SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-276858
Filing Date
2022-11-03
Accepted
2022-11-03 16:00:32
Documents
14
Period of Report
2022-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d414334d8k.htm   iXBRL 8-K 24932
2 EX-99.1 d414334dex991.htm EX-99.1 58368
6 GRAPHIC g414334dsp5.jpg GRAPHIC 4378
  Complete submission text file 0001193125-22-276858.txt   224593

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stsa-20221103.xsd EX-101.SCH 2864
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stsa-20221103_lab.xml EX-101.LAB 18739
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stsa-20221103_pre.xml EX-101.PRE 11713
8 EXTRACTED XBRL INSTANCE DOCUMENT d414334d8k_htm.xml XML 3465
Mailing Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080
Business Address 400 OYSTER POINT BOULEVARD SUITE 221 SOUTH SAN FRANCISCO CA 64080 415-505-0809
Satsuma Pharmaceuticals, Inc. (Filer) CIK: 0001692830 (see all company filings)

IRS No.: 813039831 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39041 | Film No.: 221357787
SIC: 2834 Pharmaceutical Preparations